Screening for cervical cancer: A modeling study for the us preventive services task force

Journal of Lower Genital Tract Disease

Volumn 17, Issue 2, 2013, Pages 193-202

  Kulasingam, Shalini L ^a,b,c,d   Havrilesky, Laura J ^c,d   Ghebre, Rahel ^e   Myers, Evan R ^c,d  

^a Minnesota Evidence based Practice Center   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c DUKE UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cervical cancer screening; Decision; Modeling

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; FALSE POSITIVE RESULT; FEMALE; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL LABORATORY TECHNIQUES; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PREVENTIVE MEDICINE; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84876139452     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3182616241     Document Type: Article

References (14)

1. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available at: http://seercancergov/csr/1975-2008/. Accessed March 15, 2012.
2. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8: 755-63.
3. Moyer VA. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;156: 880-91.
4. Koliopoulos G, ArbynM, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007 ;104: 232-46.
5. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-71.
6. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Rockville, MD: U.S. Preventative Services Task Force; 2011.
7. American Society for Colposcopy and Cervical Pathology (ASCCP). Consensus Guidelines2006 Available from: http://www.asccp.org/consensus.shtml. Accessed October 15, 2010.
8. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197: 346-55.
9. Vesco K, Whitlock E, Eder M, Lin J, Burda B, Senger C, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U. S. Preventive Services Task Force. Evidence Synthesis No 86 AHRQ Publication No 11-05156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
10. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357: 1579-88.
11. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149: 659-69.
12. Gold MR, Russell LB,WeinsteinMC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
13. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
14. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291: 2100-6.